Articles On Orthocell (ASX:OCC)

The S&P/ASX 200 Index (ASX: XJO) is out of form and on course to record a decline. At the time of writing, the benchmark index is down 0.4% to 8,811.4 points. Four ASX shares that are not letting that hold them back are listed below. H...

The S&P/ASX 200 Index (ASX: XJO) had a volatile and ultimately unsuccessful Tuesday session today. After spending time in both positive and negative territory this session, the bears won out in the e...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a small gain. At the time of writing, the benchmark index is up 0.1% to 8,872 points. Four ASX shares that are rising more than most today are listed below. He...

While global headlines are dominated by trillion-dollar giants, one ASX small cap is quietly making big strides in artificial intelligence. AI-Media Technologies Ltd (ASX: AIM) has built its business on live captioning and translation servi...

Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds. In this episode, host Tylah Tully unpacks the latest news from Orthocell (ASX:OCC), who has appointed its first Canadian distributor for Remplir, as it pu...

Restaurant Brands New Zealand Ltd (ASX: RBD) has received a takeover offer from its majority shareholder at a massive 64% premium to the last trading price. The company, whose Australian-listed shares were valued at $336.8 million at Mon...

Orthocell Ltd (ASX: OCC) shares are having a strong start to the day. In morning trade, the small cap ASX share is up over 8% to $1.35. Why is this ASX share jumping on Tuesday? Investors have been bidding the regenerative medicine company'...

You make your own luck – and 4D Medical (ASX:4DX) has enjoyed that commodity in shovel-loads over the last month. It all started in August when the lung scanning innovator inked a deal with the giant ASX-listed Pro Medicus, involving a $10...

ASX crawls up just 0.17pc with 7 sectors lower Healthcare sharply lower as Trump threatens tariffs on pharmaceuticals Strength in resources and banks outweighs greater market losses   Markets take stock as tariffs fire back up After a pol...

Management “couldn’t be happier” with the early US rollout of its flagship device, Remplir Revenue should start slowly but then escalate rapidly in ‘hockey stick’ style Following Remplir’s surprise adoption in prostate surgery, Orthocell e...

FDA classifies medical devices based on the type of device and the level of risk it poses Three main FDA clearances for medical devices are 510(k), de novo and pre-market approval  Several ASX companies have recently been granted FDA clear...

DroneShield Ltd (ASX: DRO) shares were trading more than 3% higher on Tuesday after the company said it had now sold more than 4000 systems worldwide. The anti-drone technology company said in a statement to the ASX that it had passed th...

ASX closes in the green on positive trading day for energy and resources Big-gun miners help bring bourse back out of the tunnel Goldies rally, too – and we may as well keep this bullet point as standard for the moment   The ASX closed 0....

Good Afternoon and Welcome to HotCopper’s Market Close for Tuesday 16 September, I’m Jon Davidson. The index came back to life on Tuesday after Wall Street notched fresh records overnight, US futures just in the green once more in the f...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Potential to reduce the risk of erectile dysfunction and urinary incontinence PERTH,...

Australian urologists are now using Orthocell’s flagship nerve repair product during prostate cancer surgery in what the WA biotech says has potential to reduce the risks of erectile dysfunction.

Orthocell Ltd (ASX: OCC) shares are outperforming the market on Tuesday. The ASX All Ords stock is currently up 10% to $1.21. This follows the regenerative medicine company announcing a major new application for its flagship nerve repair de...

Orthocell (ASX:OCC) shares popped +10% on Tuesday as the company reported its flagship nerve repair product, Remplir, is being used by some Australian urologists in seeking to mitigate complications that typically follow prostate cancer sur...

Australian urologists are using Orthocell’s flagship nerve repair product Remplir in prostate cancer surgery Remplir holds promise in reducing post-surgical complications due to peripheral nerve injury Up to 80% of men experience erectile...

Regenerative medicine company Orthocell (ASX: OCC) has introduced its flagship nerve repair device Remplir to Australian urologists for use in nerve-sparing robotic-assisted radical prostatectomies (RARP). Currently up to 80% of men experie...

The All Ordinaries Index (ASX: XAO) has gained 4.0% since market close on 9 July, but one ASX All Ords stock has left those gains in the dust. The surging stock in question is respiratory imaging technology company 4DMedical Ltd (ASX: 4DX)....

DroneShield Ltd (ASX: DRO) shares are tumbling today. Shares in the S&P/ASX 300 Index (ASX: XKO) drone defence company – which will join the S&P/ASX 200 Index (ASX: XJO) on 22 September – closed yesterday trading for $3.21. In early...

The S&P/ASX 200 Index (ASX: XJO) is having a better session on Wednesday. In afternoon trade, the benchmark index is up 0.3% to 8,828.3 points. Four ASX shares that have failed to follow the market higher today are listed below. Here's...

S&P/ASX 200 Index (ASX: XJO) stocks are up 0.27% to 8,827.1 points on Wednesday. The ASX 200 has slipped 1.6% since the start of what is traditionally a weaker month for the market. On The Bull this week, experts have identified f...

Tylah Tully chats with Orthocell (ASX:OCC) CEO and managing director Paul Anderson after a new real-world study demonstrated a 81.1% treatment success rate for the company’s nerve repair device, Remplir. Anderson explains why this real-worl...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Data to support US sales roll out and EU + UK regulatory submissions  Interim resu...

ASX closes 0.24% lower on Monday with tech leading gainers and energy the laggards Asian markets climb higher led by Tokyo after Japanese Prime Minister Shigeru Ishiba announces resignation Supermarket giants Coles and Woolworths face heft...

Interim results from Orthocell’s new Remplir study demonstrate treatment success rate of 81.1% following nerve repair procedures Results confirm Remplir as ideal for connecting severed nerves, protecting damaged nerves or capping nerves af...

The S&P ASX 200 Health Care index fell 13.21% in August as a tough reporting season weighed on sector CSL had its biggest ever one day fall on August 19, down 17% following softer FY25 results and restructure plans Despite the broader...

Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds. In this episode, host Tylah Tully looks at Orthocell (ASX:OCC), whose nerve repair product Remplir is continuing its strong US market momentum with increa...

Avita shares jump up to 13% after the company’s $23 million equity raising   EBR Systems narrows June quarter loss Orthocell is on track with its US rollout   Burns and woundcare outfit Avita Medical (ASX:AVH) has answered concerns about...

Despite myriad pressures under the Trump regime, the FDA’s drug and device approval process largely has been unfettered Telix Pharmaceuticals expects a company-making approval decision by the end of the month Painchek is among a string of...

The S&P ASX 200 Health Care index rose 9.05% in July with rotation into the sector gaining momentum  Lumos soared 170% in July after six-year exclusive deal valued at up to US$317 million with PHASE Scientific for distribution of Febri...

Highlights Orthocell announces director resignation due to health, maintains advisory support Lanthanein completes drilling phase at Lady Grey Project in Western Australia Aurum and Asian Battery Metals report progress acros...

  Experienced corporate leader Michael McNulty will join the board as a non-executive director and chair of audit committee US-based independent non-executive director Dr Ravi Thadhani elevated to lead independent director Former oppositio...

Former WA governor and US ambassador Kim Beazley will step down from the board of Perth regenerative medicine company Orthocell due to health reasons.

ASX industrials shares grew significantly in FY 25. The S&P/ASX 200 Industrials Index (ASX: XNJ) is up almost 10% since January.  Broker Bell Potter has identified two ASX industrials shares that are currently undervalued, placin...

Evolution Mining Ltd (ASX: EVN) shares have been very strong performers over the past 12 months. In fact, the ASX 200 gold stock has rocketed approximately 90% since this time last year. This has almost doubled its market capitalisation to...

DroneShield Ltd (ASX: DRO) shares are starting the week with a bang. In morning trade, the counter drone technology company's shares are up over 11% to a new record high of $3.09. Why are DroneShield shares rocketing? Investors have been bi...

On Thursday, the S&P/ASX 200 Index (ASX: XJO) had a good session and charged higher. The benchmark index rose 0.6% to 8,589.2 points. Will the market build on this on Friday and end the week on a high? Here are five things to watch: ASX...

Highlights Novo Resources identifies high-grade gold intercepts at Tibooburra Gold Project in NSW Orthocell reports record FY2025 revenue, advancing regenerative medicine footprint Resolution Minerals gears up for major dril...

ASX shrugs off tariff pessimism to climb 0.59pc Gains led by gold and banking stocks Major banks join RBA stablecoin project   Gold and Banks lead ASX charge Let’s see – a 50% tariff on copper, up to 200% on pharmaceuticals, and maybe mor...

Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds. In this episode, host Tylah Tully takes a look at Orthocell (ASX:OCC), who have achieved first US revenue from Remplir, its flagship nerve repair product,...

Good Afternoon and welcome to HotCopper’s Market Close for Thursday 10th of July, I’m Jon Davidson.  It was a green day at least, but still below 8,600 points, we’re yet to return to recent glories. The big thing to note in my view is th...

Trigg Minerals (ASX:TMG) has drawn the most attention on the HotCopper forums through Thursday trade after the mining company mysteriously halted just before open. Holders were left “a bit worried” across the boards. Listen to the HotCop...

Platinum Asset Management Ltd (ASX: PTM) shares are having a day to remember on Thursday. In afternoon trade, the fund manager's shares are up 13% to 56 cents. Why are Platinum shares rocketing? Investors have been scrambling to buy the com...

The S&P/ASX 200 Index (ASX: XJO) is back on form and charging higher on Thursday. In afternoon trade, the benchmark index is up 0.8% to 8,607.4 points. Four ASX shares that are rising more than most today are listed below. Here's why th...

The Australian share market is back on form on Thursday. In morning trade, the All Ordinaries index is up 0.5% to 8,823.2 points. One ASX All Ords stock that is outperforming the index is named below. Let's see why its shares are jumping to...

The boss of WA regenerative medicine company Orthocell has labelled Donald Trump’s latest tariff threat on pharmaceuticals as a ‘cage-rattling exercise’ to try elicit panic from the Australian Government.

POTUS threatens a foreign drug tariff, but gives Big Pharma more time to shift production onshore ASX drug makers say they won’t be overly affected by any Trump tariff whack Island Pharma acquires a secondary virus program   Donald Trump...